Harvard Pilgrim excludes all weight-loss drugs; BCBS of Massachusetts and BCBS of Michigan narrow coverage

Three regional health insurers began 2026 by cutting coverage for GLP-1 medications used for weight loss. Harvard Pilgrim Health Care excluded all weight-loss drugs, including GLP-1s, effective January 1, 2026 ^[1]. Blue Cross Blue Shield of Massachusetts ended coverage of GLP-1s for anything other than type 2 diabetes as plans renew starting January 1, 2026 ^[2]. Blue Cross Blue Shield of Michigan also dropped weight-loss GLP-1 coverage ^[3][4].

What each insurer changed

Harvard Pilgrim's notice to Massachusetts small-group customers says the plan "will exclude coverage of all weight loss drugs, including GLP-1 drugs, to treat weight loss and related conditions, such as cardiovascular disease," and that GLP-1s remain covered only when prescribed for diabetes ^[1]. Harvard Pilgrim sells plans in Maine, Massachusetts, Rhode Island and New Hampshire, and the change applies to most commercial plans ^[3]. Large fully insured employers with more than 100 employees can pay extra to keep coverage; members on those plans must complete a six-month behavioral modification program before getting the medication, unless they are already taking it ^[3]. A Harvard Pilgrim spokesperson said the move was tied to "current pipeline of pending future FDA approvals of weight loss medications for alternative indications including cardiovascular conditions and other comorbidities," and was taken "to ensure affordability of coverage for all our members" ^[3].

Blue Cross Blue Shield of Massachusetts drew the line at employer size. Employers with more than 100 employees may choose to continue coverage at added cost; companies with fewer than 100 employees and direct-pay members are not eligible to continue it ^[2][3]. The policy covers both self-insured and fully insured employers ^[3]. When coverage ends at renewal, existing prior authorizations expire and Wegovy, Saxenda and Zepbound are no longer covered ^[2]. The insurer says this is a benefit exclusion that cannot be appealed ^[2]. Ozempic, Mounjaro, Trulicity and other GLP-1s approved for type 2 diabetes remain covered, still with prior authorization requiring a documented diabetes diagnosis ^[2]. BCBSMA says it will contact affected members no later than 60 days before their renewal date, and that premiums will not go down as a result ^[2]. Members with individual Medex plans that include Part D drug coverage lose weight-loss GLP-1 coverage in 2026 as well ^[2].

The stated reason is price. List prices for GLP-1s run roughly $936 to $1,349 a month before rebates or discounts ^[3], or about $900 to $1,400 by another accounting ^[4]. BCBSMA spokesperson Kelsey Pearse said the decision responds to "customers who've expressed to us that they are no longer able to bear the burden of paying for these high-priced medications" ^[3]. The insurer says it approached manufacturers about lower prices without success ^[2].

Why it matters for patients

If your employer plan drops the benefit, the practical result is that a drug that cost a copay may now cost hundreds of dollars a month out of pocket. BCBSMA points members toward manufacturer savings programs, HSA or FSA funds, nutrition counseling, care management, fitness and weight-program reimbursements, and bariatric surgery for members with obesity-related health risks ^[2]. Dr. Angela Fitch, an obesity medicine physician and former president of the Obesity Medicine Association, said when patients lose coverage she has to direct them to cash-pay options such as NovoCare or LillyDirect, or switch them to older medications that may require more visits and cause more side effects ^[3].

Coverage status also depends on details many people do not track: employer headcount, plan renewal date, and whether the prescription is written for diabetes or weight. Diabetes prescriptions are unaffected at both Massachusetts insurers ^[1][2]. Appeals are not an option at BCBSMA because the change is written as a benefit exclusion rather than a medical-necessity denial ^[2].

The trend is broader than New England. North Carolina's Medicaid program rolled back weight-management GLP-1 coverage ^[3][4], Medicare does not cover GLP-1s for weight loss ^[3], and among ACA marketplace plans only 26 of 300 carriers offer the coverage, with enrollment in plans that include it falling from 3.6 million in 2024 to 2.8 million in 2026 ^[4]. Among self-insured employers, 73% still cover GLP-1s for obesity and 99% for diabetes ^[3].

What happens next

BCBSMA says employers with more than 100 employees will make their own coverage decisions "in the coming months," with member notice at least 60 days before renewal ^[2]. Because changes take effect at each plan's renewal date, not all at once on January 1, some members will not feel the change until later in 2026 ^[2]. How many people lose coverage overall is not yet known; no definitive count of insurers and employers dropping coverage exists ^[3].